Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: A CORIST-ANRS HC1 trial

Clinical Infectious Diseases

Volumn 36, Issue 10, 2003, Pages 1295-1304

  Salmon Céron, Dominique ^a   Lassalle, Régis ^b   Pruvost, Alain ^c   Benech, Henri ^c   Bouvier Alias, Magali ^d   Payan, Christopher ^e   Goujard, Cécile ^f   Bonnet, Eric ^g   Zoulim, Fabien ^h   Morlat, Philippe ⁱ   Sogni, Philippe ^a   Pérusat, Sophie ^b   Tréluyer, Jean Marc ^a   Chêne, Geneviève ^b  

^a université Paris Cité   (France)

^b INSERM   (France)

^c DIF   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f BICÊTRE HOSPITAL   (France)

^g CHU PURPAN   (France)

^h South Lyon Hospital   (France)

ⁱ HÔPITAL SAINT ANDRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; STAVUDINE; VIRUS RNA;

ADULT; ANEMIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; LIQUID CHROMATOGRAPHY; LYMPHOCYTE COUNT; MALE; MASS SPECTROMETRY; MONONUCLEAR CELL; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUPERINFECTION;

ADULT; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; INTERFERONS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0038183828     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/374837     Document Type: Article

References (22)

1. Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibodies to hepatitis C virus in patients infected with the human immunodeficiency virus. J Infect Dis 1991; 163:414-5.
2. Salmon-Céron D, Gouël P, Dellaroque-Astagneau E, et al. Hospitalized HIV-HCV-coinfected patients: a French national survey made in June 2001. Med Mal Infect 2003; 33:78-83.
3. Hayashi PH, Flynn N, McCurdy SA, Kuramoto IK, Holland PV, Zeldis JB. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991; 33:177-80.
4. Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350:1425-31.
5. Di Perri G, Raiteri R, Bonora S, et al. Liver failure from HCV as the current leading cause of death in HIV-infected patients in Northern Italy [abstract 573]. In: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
6. Lewden C, Héripret L, Bonnet F, et al. Causes of death in HIV-infected adults in the era of HAART the French survey "Mortality 2000" [abstract 753W]. In: CROI editor. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.
7. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987; 235:1376-9.
8. Hoggard PG, Barry MG, Khoo SH, Back DJ. Drug interactions with d4T phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-6.
9. Hoggard PG, Veal GJ, Wild MJ, Barry MG, Back DJ. Drug interactions with zidovudine phosphorylation in vitro. Antimicrob Agents Chemother 1995; 39:1376-8.
10. Sim SM, Hoggard PG, Sales SD, Philboonbanakit D, Hart CA, Back DJ. Effect of ribavirin on zidovudine efficacy and toxicity in vitro: a concentration-dependent interaction. AIDS Res Hum Retroviruses 1998; 14:1661-7.
11. Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2′,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997; 41:1231-6.
12. Zylberberg H, Benhamou Y, Lagneaux JL, et al. Safety, and efficacy of interferon ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut 2000; 47:694-7.
13. Landau A, Batisse D, Piketty C, Kazatchkine M. Effect of interferon and ribavirin on HIV viral load. AIDS 2000; 14:96-7.
14. Bochet M, De Torres M, Valantin MA, et al, for the MULTIVIRC Group. Efficacy and tolerance of alfa-IFN plus ribavirin for chronic hepatitis C [abstract 574]. In: CROI editor. Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 2001.
15. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000; 182:599-602.
16. Erali M, Hillyard DR. Evaluation of the ultrasensitive Roche Amplicor HIV-1 monitor assay for quantification of human immunodeficiency virus type-1 RNA. J Clin Microbiol 1999;37:792-5.
17. Pruvost A, Becher F, Bardouille P, et al. Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography tandem mass spectrometry. Rapid Commun Mass Spectrom 2001; 15:1401-8.
18. Becher F, Pruvost A, Goujard C, et al. Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2002; 16:555-65.
19. McHutchison J, Gordon S, Schiff E. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for the hepatitis in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-92.
20. Poynard T, Marcellin P, Less SS. Randomized trial of interferon-α-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon-α-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
21. Manns MP, MacHutchison JG, Gordon SC. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958-65.
22. Chung R, Andersen B, Alston B, et al. A randomized, controlled trial of pegylated interferon-α-2a with ribavirin versus interferon-α-2a with ribavirin for the treatment of chronic HCV in HIV co-infection [abstract LB15]. In: CROI editor. Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). Alexandria, VA: Foundation for Retrovirology and Human Health, 2002.